Understanding of Psychotic Disorders in Children With 22q11.2DS (PremiCeS22)
Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Véronique VIAL
- Phone Number: +33 0437915531
- Email: veronique.vial@ch-le-vinatier.fr
Study Contact Backup
- Name: Caroline DEMILY, MD PH
- Phone Number: +33 0450915163
- Email: caroline.demily@ch-le-vinatier.fr
Study Locations
-
-
Rhone Alpes
-
Lyon, Rhone Alpes, France, 69678
- Recruiting
- Hopital Vinatier
-
Contact:
- VIAL VERONIQUE
- Phone Number: 0033437915531
- Email: veronique.vial@ch-le-vinatier.fr
-
Contact:
- DEMILY MD CAROLINE, PH
- Phone Number: 0033437915163
- Email: caroline.demily@ch-le-vinatier.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of 22q11.2 deletion syndrome or no developmental disease
- Aged from 4 to 13 years old
- French language
Exclusion Criteria:
- Diagnosis of intellectual deficiency according to DSM 5 criteria
- Drug prescribed for somatic condition that could influence cerebral functioning
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 22q11.2DS
Children aged from 4 to 13 years old with 22q11.2
deletion syndrome
|
Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
|
|
Active Comparator: Control Group (Non22q11.2DS)
Children aged from 4 to 13 years old without developmental disease
|
Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Screen for child Anxiety Related Emotional Disorders (SCARED)
Time Frame: Day 1
|
Scale assessing behavioral prodromes or warning signs of hallucinations in psychotic disorders A psychometric study is then carried out on this questionnaire in order to validate it with parents of children carrying 22q11.2DS.
|
Day 1
|
|
facial expression recognition task
Time Frame: Day 1
|
Proportion of correct responses in experimental tasks evaluating gaze direction and facial expression recognition
|
Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sustained hearing attention test (Tea-Ch battery)
Time Frame: Day 1
|
Proportion of impaired scaled score at the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch)
|
Day 1
|
|
Rey's Tangled Lines Test
Time Frame: Day 1
|
Proportion of impaired scaled score to study the degree of cognitive development in children
|
Day 1
|
|
NEPSY II battery
Time Frame: Day 1
|
Proportion of impaired scaled score at auditory attention of NEPSY II battery The NEPSY-II is a comprehensive neuropsychological battery for children ages 3-12.
The test provides measures of sensor-motor, language, visuospatial processing, memory and learning, attention/executive functions, and social cognition.
|
Day 1
|
|
Mean reaction time
Time Frame: Day 1
|
Mean reaction time in neuropsychological testing and experimental tasks
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Marie-Noëlle BABINET, CH le Vinatier
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Musculoskeletal Diseases
- Cardiovascular Diseases
- Schizophrenia Spectrum and Other Psychotic Disorders
- Heart Diseases
- Genetic Diseases, Inborn
- Lymphatic Diseases
- Craniofacial Abnormalities
- Musculoskeletal Abnormalities
- Congenital Abnormalities
- Parathyroid Diseases
- Cardiovascular Abnormalities
- Heart Defects, Congenital
- Abnormalities, Multiple
- Chromosome Disorders
- Lymphatic Abnormalities
- Hypoparathyroidism
- 22q11 Deletion Syndrome
- Psychotic Disorders
- Mental Disorders
- DiGeorge Syndrome
Other Study ID Numbers
Other Study ID Numbers
- 2020-A01370-39
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.